Minimal Residual Disease Patents

Minimal/measurable residual disease (MRD) patents cover ultra-sensitive ctDNA-detection innovations; tumor-informed (personalized) innovations; tumor-naive innovations; and blood-cancer MRD, serial-monitoring, and §101 innovations — with IP held by precision-oncology diagnostics companies (in a field detecting tiny amounts of residual cancer after treatment, below what imaging can see). WHY MRD: after cancer treatment, a patient may look 'cancer-free' on scans yet harbor MINIMAL RESIDUAL DISEASE (a few remaining tumor cells) that drives recurrence; MRD testing detects this — mainly via CIRCULATING TUMOR DNA (ctDNA) in blood (or immune-repertoire for blood cancers) — to guide whether to escalate/de-escalate therapy, monitor for recurrence MONTHS earlier than imaging, and assess treatment response; it's a fast-growing, high-value precision-oncology application. MAJOR MRD PATENT HOLDERS: NATERA (Signatera — TUMOR-INFORMED ctDNA MRD, the market leader), GUARDANT HEALTH (Guardant Reveal — TUMOR-NAIVE ctDNA MRD), ADAPTIVE BIOTECHNOLOGIES (clonoSEQ — MRD for BLOOD cancers via immune-receptor sequencing), PERSONALIS (NeXT Personal — ultra-sensitive whole-genome-informed), FOUNDATION MEDICINE, INIVATA/NeoGenomics. Ultra-sensitive detection, tumor-informed, tumor-naive, and blood-cancer/serial/§101 are the core MRD patent domains — and ultra-sensitive detection, tumor-informed assays, and serial-monitoring methods are the open whitespace.

Ultra-sensitive ctDNA-detection innovations; tumor-informed (personalized panel) innovations; tumor-naive innovations; and limit-of-detection/error-suppression innovations represent core MRD patent domains — and detecting a VANISHINGLY tiny amount of tumor DNA (and the tumor-informed vs tumor-naive strategy) are the central technical battlegrounds. ULTRA-SENSITIVE ctDNA-DETECTION PATENTS: MRD requires detecting CANCER DNA at extremely low fractions (often <0.01% — a few mutant molecules among millions of normal) — ERROR SUPPRESSION (distinguishing true mutations from sequencing errors via molecular barcodes/duplex sequencing/consensus), deep sequencing, and statistical detection; ultra-sensitive detection (the lowest limit of detection, LOD) is the core, high-value technical IP (sensitivity is everything for MRD). TUMOR-INFORMED (PERSONALIZED PANEL) PATENTS: sequencing the PATIENT'S OWN TUMOR first, then designing a BESPOKE/personalized assay tracking THAT patient's specific mutations in blood (tracking many patient-specific variants boosts sensitivity/specificity — Natera Signatera); tumor-informed personalized assay design is high-value, differentiating IP (a leading approach). TUMOR-NAIVE PATENTS: detecting MRD WITHOUT the patient's tumor tissue — fixed gene panels or METHYLATION-based detection (Guardant Reveal) — faster/no-tissue-needed but typically less sensitive; tumor-naive methods are a distinct, valuable approach. LOD / ERROR-SUPPRESSION PATENTS: pushing the limit of detection lower while controlling false positives (specificity) — the fundamental sensitivity-specificity tradeoff. Ultra-sensitive ctDNA detection (LOD/error suppression), tumor-informed personalized assays, and tumor-naive methods are the highest-value core IP because detection sensitivity and the tumor-informed/naive strategy determine MRD's clinical accuracy and competitiveness.

Blood-cancer (immune-repertoire) MRD innovations; serial-monitoring/recurrence innovations; clinical-application innovations; and §101 and validation considerations represent additional MRD patent domains — and MRD for blood cancers, tracking patients over time, and the patent-eligibility landscape are key. BLOOD-CANCER (IMMUNE-REPERTOIRE) MRD PATENTS: for blood cancers (leukemia/lymphoma/myeloma), MRD is detected by SEQUENCING the IMMUNE RECEPTOR repertoire — identifying and tracking the cancer clone's unique rearranged immune-receptor sequence (Adaptive clonoSEQ — the FDA-cleared blood-cancer MRD standard); immune-repertoire MRD is a distinct, high-value approach (different biology from solid-tumor ctDNA). SERIAL-MONITORING / RECURRENCE PATENTS: MRD's power is LONGITUDINAL — testing repeatedly over time to detect recurrence MONTHS before imaging, track treatment response, and trigger intervention; serial-monitoring methods, dynamics/kinetics analysis, and recurrence prediction are valuable. CLINICAL-APPLICATION PATENTS: using MRD to guide care — ADJUVANT therapy decisions (escalate if MRD+, de-escalate/avoid chemo if MRD−), surveillance, and therapy-response assessment; clinically-actionable MRD applications/methods are high-value. §101 / VALIDATION CONSIDERATIONS: like NIPT/liquid biopsy, MRD ctDNA-detection methods face §101 ABSTRACT-IDEA/natural-phenomenon scrutiny (Ariosa/Mayo — detecting natural ctDNA with conventional sequencing risks ineligibility) — so claim NOVEL technical methods (error suppression, personalized assay design, specific techniques) rather than the abstract detection; and clinical VALIDATION (sensitivity/specificity, outcome correlation, FDA/reimbursement) is essential. Blood-cancer immune-repertoire MRD, serial-monitoring/recurrence methods, and §101-defensible technical claims are the highest-value application IP because immune-repertoire MRD, longitudinal monitoring, and eligibility-robust claims define MRD's distinct value and patentability.

MRD startup IP strategy must navigate Natera/Guardant/Adaptive's strong, litigated portfolios (MRD/ctDNA is a competitive, patent-contested space — Natera has litigated competitors), ctDNA/liquid-biopsy prior art, the §101 eligibility problem (detecting natural ctDNA), the SENSITIVITY (LOD) and specificity challenges, the tumor-informed-vs-tumor-naive strategy, the clinical-validation/reimbursement realities, and a landscape where ultra-sensitive detection, tumor-informed assays, blood-cancer MRD, and serial monitoring are the durable assets; understand that ctDNA detection is well-trodden and §101-constrained, so the durable IP is in ultra-sensitive detection/error-suppression, tumor-informed personalized assay design, immune-repertoire MRD, serial-monitoring methods, and §101-eligible technical claims, and that sensitivity, clinical validation, reimbursement, and FTO matter as much as patents; identify whitespace in ultra-sensitive detection, tumor-informed assays, and serial monitoring. MRD STARTUP IP STRATEGY: ctDNA DETECTION IS WELL-TRODDEN AND §101-CONSTRAINED — ULTRA-SENSITIVE DETECTION, TUMOR-INFORMED ASSAYS, IMMUNE-REPERTOIRE MRD, AND SERIAL MONITORING ARE THE IP: patent error-suppression/ultra-sensitive detection, personalized assay design, and serial methods — claimed as NOVEL technical methods (not abstract ctDNA detection, per §101/Ariosa); ULTRA-SENSITIVE DETECTION (LOD) IS THE CORE TECHNICAL BATTLEGROUND: MRD lives or dies on detecting cancer DNA at <0.01% — error suppression (barcodes/duplex/consensus) and the lowest LOD are the most valuable, defensible IP; TUMOR-INFORMED PERSONALIZED ASSAYS ARE A LEADING, HIGH-VALUE APPROACH: bespoke tracking of a patient's own mutations (Signatera) boosts sensitivity/specificity — personalized assay-design IP is high-value (and Natera defends it); TUMOR-NAIVE IS A DISTINCT (FASTER/NO-TISSUE) PATH: fixed-panel/methylation MRD (Guardant Reveal) avoids needing tumor tissue — different IP and clinical fit; IMMUNE-REPERTOIRE MRD OWNS BLOOD CANCERS: clonoSEQ-type immune-receptor sequencing (Adaptive) is the blood-cancer standard — distinct biology/IP; SERIAL MONITORING IS MRD'S UNIQUE VALUE: longitudinal recurrence detection (months before imaging) and response tracking are valuable, patentable methods; §101 SHAPES CLAIMS — AND THE SPACE IS LITIGIOUS: claim concrete novel techniques (not natural ctDNA detection), and clear FTO (Natera/Guardant/Adaptive litigate); VALIDATION/REIMBURSEMENT GATE THE BUSINESS: clinical evidence (outcome correlation), FDA, and reimbursement (Medicare coverage drives adoption) matter as much as patents; WHEN TO PATENT (WITH §101 AND FTO IN MIND): NOVEL DETECTION/ASSAY/MONITORING WITH MEASURED PERFORMANCE: file once a method shows measured results (limit of detection (% / molecules) + sensitivity/specificity + tumor-informed/naive performance + serial-monitoring lead time vs imaging + clinical outcome correlation) AND can be claimed as a novel technique — measured LOD/sensitivity-specificity, tumor-informed performance, and recurrence lead-time are the critical MRD IP metrics; KEY FTO CHECKLIST: Natera Signatera tumor-informed ctDNA (LITIGATED — FTO); Guardant Reveal tumor-naive; Adaptive clonoSEQ immune-repertoire blood-cancer; Personalis NeXT Personal ultra-sensitive; ultra-sensitive ctDNA error-suppression/molecular-barcode/duplex/consensus/LOD; tumor-informed personalized bespoke panel design; tumor-naive fixed-panel/methylation; immune-receptor repertoire sequencing (blood cancer); serial/longitudinal monitoring/recurrence/kinetics; adjuvant-therapy/surveillance clinical application; §101 Ariosa/Mayo natural-ctDNA eligibility; clinical validation/FDA/reimbursement; liquid-biopsy prior art + MRD litigation.